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In ominous projections issued by both U.S. Public Health Service and the World
Health Organization, the epidemic of HIV infection will continue to rise more rapidly
worldwide then predicted earlier. The AIDS patients are susceptible to diseases called
opportunistic infections of which tuberculosis and M. aviun! Complex (MAC) infection
are most common. This has created an urgent need to uncover new drugs for the
treatment of these infections.
In the seventies, NASA scientists at Goddard Space Flight Center, Greenbelt,
Maryland, had adopted a biochemical indicator, adenosine triphosphate (ATP), to detect
presence of life in extraterrestrial space. We proposed to develop ATP assay technique to
determine sensitivity of antibacterial compounds against MAC and M. tuberculosis.
The work was initiated in June 1992. Going through the recent literature, we
observed most of the work on ATP was related to bacteria other than mycobacteria. First,
there are more than a dozen models of commercially available luminometers; however,
all of them use their own reagents, composition of which is not disclosed. So, it was
decided to use the Aminco Chem-Glow Photometer for the assay of ATP by
bioluminescence technique, since this instrument can be used manually and is very
flexible.
REAGENTS:
Most commercial reagents are provided as a mixture of luciferase & D-lucifer'in.
These gave excessive background light due to impurities in luciferase, and so we decided
to prepare our own bioluminescent system.
Luciferase-containing firefly lantern extract (Sigma Chemical Company) was first
dissolved in Tris-acetate buffer, pH 7.7 (containing EDTA and 0.5% bovine serum
albumin), and passed through G-200 Sephadex column at 4"C. To determine active
fractions after elution with the same buffer, 0.2 ml aliquot from each fraction was mixed
with 0.1 ml of luciferin solution (400/_g/ml) in the assay cuvette, and to this 0.1 ml of
standard ATP solution (100 pg ATP) was injected. Any fraction giving a peak height of
75-100mmon therecordingchartwasconsideredasactivefraction. All theactive
fractionswereix_oledtogetherandmixedwith appropriateamountof luciferin. After
gentlemixing, the luciferase-luciferinsystemwasincubatedfor four hoursat25°Cin the
darkto permitATPcontaminatingin firefly lantern extract to "burn off _ to a negligible
concentration. The aliquots were then dispensed in amber vials and stored at -20°C. This
system reproducibly detected 10 pg ATP/0.1 ml and gave a linear response up to 10,000
pg ATP/0.1 ml. Thus, this system improved the sensitivity by three logs and was 10-15
times less expensive than commercially available preparations. Supplementing this
system with additional luciferin did not enhance the sensitivity appreciably.
EXTRACTING AGENTS"
M. avium strain 9141 (serovar 8) was used for all initial studies. It was grown in
Middlebrook 71-19 broth and 71-110 agar plates. The broth suspension was diluted to
obtain f'mal concentration of lxl07 CFU (colony forming units) per ml. For each
extraction, 0.1 ml bacterial suspension was centrifuged for 20 minutes at 3,000 rpm;
sedimented bacteria were washed twice with 0.05 M "Iris buffer, pH 7.75 and finally
suspended in the same buffer as desired.
After completing extensive literature search, six extracting agents were selected to
extract intracellular ATP from M. avium complex (MAC) and M. tuberculosis (Mtb).
These were Tris-EDTA, trichloroacetic acid, Perchloric acid, dimethyl sulfoxide, butanol
and chloroform. The optimal extracting procedure was to expose bacteria to chloroform
at 100"C for 10 minutes. This method did not inactivate standard ATP, and recovery
from bacteria was 94-98%. Also, it was determined that various steps (to be used with
sputum and blood samples) such as decontamination with NaOH and removal of
mammalian ATP with Triton X- 100 had no effect on standard ATP. The ATP content
from 106 cells of M. a_um and M. tuberculosis was 544 pg and 572 pg. respectively.
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Relationship between bacterial counts and ATP levels:
Using MAC, excellent correlation (coefficient of correlation of 0.946) was
obtained between the standard colony count method (7-10 days) and ATP levels (2-3
hours). Next, ATP measurements were made using both MAC and Mtb during the
growth cycle. Within 12 hours of incubation (lag phase) the ATP levels showed increase.
Again, during logarithmic phase, the increase in colony counts was proportional to
increase in ATP levels, while in death phase, decline in ATP levels were more obvious
than the colony counts.
Effect of antimycobacterial dru_:
Using common antimycobacterial agents, killing effects of the drug were similar
using plate counts and ATP method; however, the minimal inhibitory concentrations
(MICs) of these drugs were lower when ATP method was used compared to those
obtained with the standard colony count method suggesting higher sensitivity of ATP
method. The killing effect of rifampicin on MAC was observed within 24 hours using
ATP method, while similar effect was seen four days later using plate count method,
again suggesting superiority of ATP method over plate count. Similar observations were
also made with Mth exposed to streptomycin. Drug susceptibility testing was performed
on 12 clinical isolates of Mtb using four standard drugs. The results of ATP assay were
available after five days of incubation in conWast to three weeks for standard colony
count method. The results by both methods agreed well, except that inhibition of M.
tuberculosis by ATP method was observed with lower concentration of drugs compared
to that observed by colony count method. Nevertheless, same strains were identified as
drug-resistant by both the methods.
Next, ATP method was compared with another standard method, BACTEC, using
14C paimitic acid. MAC and M. tuberculosis were inoculated into 7H9 broth (for ATP
assays), 7I-I11 agar for plate counts and 7H12 broth with l'_C-palmitic acid for BACTEC,
each containing various concentrations of antimycobacterial drugs added singly. The
MICs obtained by both ATP and BACTEC methods were the same, but lower than those
obtained by plate count method. However, the time to obtain reliable results with ATP
method was shorter (3-5 days) than with BACTEC method (5-7 days) and plate count
method (1-3 weeks).
The results obtained so far clearly indicate that the ATP method is somewhat
superior to colony count method, as well as BACTEC method, in screening potential anti-
mycobacterial drugs. However, advantages are (a) ATP method is more economical
compared to other two methods, and (b) ATP method does not use any radioactive
material, thus avoiding the problem of radioactive waste.
Application to clinical saecimen_:
Second part of the project involves application of ATP method to clinical
specimens. Development of methods to setmram bacteria from sputum specimens took
longer time than anticipated initially. Finally, method adopted includes digestion of
sputum with sodium lauryl sulfate and NaOH, treating digested material with a detergent,
Triton X-100, to rupture all non-bacterial cells followed by treatment with ATPase to
inactivate all non-bacterial ATP and finally, extracting bacterial ATP. Several sputum
samples from tuberculosis patients were obtained. Again, excellent correlation has been
obtained between ATP assay, colony counts and BACTF_ method, with ATP assay
demonstrating upper edge and having advantages mentioned above.
Next, several sputum specimens were obtained from randomly selected
tuberculosis patients. These were untreated in early stages and advanced stages of the
disease, as well as partially treated and also who have completed treatment regimens.
ATP method (and plate count method) could be applied to specimens from patients in
early stages; but BACTEC method could not be applied since organisms recovered from
such patients were below the sensitivity limits for BACTFA:. Also, ATP method gave
useful information on the status of patients under treatment, which could not be obtained
by BACTEC method.
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Finally, two patientsfrom aboveseries,untreatedtuberculosispatientsin early
stagesof thedisease,werefollowedduring their entiretreatmentregimenof six months
ona combinationantimycobacterialdrugs. Within onemonthof treatment,theATP
levelsshoweda significantdeclinesuggestingthefavorableresponseof patientsto the
chemotherapy.Suchinformationcouldnotbeobtainedeitherby platecountmethodor
by BACTECmethod. However, we could not continue these studies with large patient
populations for lack of funds through year three of this grant.
Florida Institute of Technology had agreed in principle to file a patent application
for the utility of ATP methods described above. Basically, three patents could have been
obtained -- one for screening newer anti-mycobacterial compounds against M.
tuberculosis and MAC; one for drug susceptibility testing for clinical specimens obtained
from tuberculosis and AIDS patients; and third for prognosis of patients under anti-
mycobacterial chemotherapy. The patent application was submitted to Research
Corporation Technologies for evaluation. According to the report of RCT's Life Sciences
Group, "while this may be the first application of this technique to mycobacterial
organisms, it is not likely that patent protection adequate for commercial purposes can be
obtained. If protection can be obtained for this in vitro assay, it is likely to be limited to a
method of use. Thus, in order to enforce that protection, it will be necessary to monitor
the activities of laboratories and individuals performing the test." Based on this
evaluation, Florida Institute of Technology decided not to pursue the patent application.
Even though NASA could not support continuation of this work for the third year,
efforts are being made to obtain funds from other sources to complete the most important
part of this project -- i.e. application of ATP method for rapid follow-up of patients
under chemotherapy.
